Intravitreal Ranibizumab Injection as an Adjuvant in the Treatment of Neovascular Glaucoma Accompanied by Vitreous Hemorrhage after Diabetic Vitrectomy
Table 1
Baseline patient characteristics.
Patient
Eye
Gender
Age (year)
Lens status
LogMAR BCVA
IOP (mmHg)
No. of antiglaucomatous medications used
PDVH after vitrectomy (weeks)
NVG after PDVH (weeks)
1
Right
Female
45
Pseudophakic
1.6
38
4
9
2
2
Left
Male
27
Phakic
1.4
26
2
4
3
3
Right
Male
54
Pseudophakic
1.6
41
3
12
1
4
Right
Male
64
Pseudophakic
2.6
51
4
22
2
5
Right
Female
32
Phakic
1.85
29
3
16
3
6
Right
Male
59
Pseudophakic
2.3
33
4
8
4
7
Left
Male
69
Pseudophakic
1.85
30
3
7
1
8
Left
Female
73
Pseudophakic
1.85
35
3
28
2
9
Right
Male
71
Pseudophakic
1.85
35
4
36
2
10
Right
Female
46
Pseudophakic
1.6
42
4
25
2
11
Left
Male
39
Pseudophakic
2.3
36
4
9
3
12
Right
Male
33
Phakic
1.5
33
3
5
4
13
Left
Male
42
Pseudophakic
1.85
47
3
16
3
14
Right
Male
66
Pseudophakic
1.85
25
2
29
2
15
Left
Male
58
Pseudophakic
2.3
35
3
23
1
16
Left
Female
44
Pseudophakic
2.6
42
4
9
1
17
Right
Female
38
Pseudophakic
2.3
40
4
5
2
18
Right
Female
62
Pseudophakic
2.6
43
4
11
2
LogMAR = logarithm of minimum angle of resolution; BCVA = best-corrected visual acuity; IOP = intraocular pressure; no. of antiglaucomatous medications used = number of antiglaucomatous medications used; PDVH = postvitrectomy diabetic vitreous hemorrhage; NVG = neovascular glaucoma.
